{"success":true,"data":{"pressRelease":{"id":"47388","rtpr_id":"nWkrbdw1Ss","ticker":"GEAN","exchange":"","all_tickers":["GEAN"],"title":"Publication of interim report January - March 2026","author":"Cision","published_at":"2026-05-28T06:45:08.456Z","article_body":"Genetic Analysis AS\nOSLO, NORWAY - May 28, 2026: Genetic Analysis AS (\"GA\" or the \"Company\")\nhereby publishes the interim report for the period January - March 2026. The\nreport is available as an attached file to this release and on the Company's\nwebsite. Below is a summary of the report.\n\nRonny Hermansen, CEO of Genetic Analysis, comments:\n“The first quarter of 2026 was marked by continued progress for Genetic\nAnalysis, with strong growth in recurring GA-map(®) kit sales and further\nadvancement of our microbiome-based diagnostics pipeline. The development\nconfirms the relevance of our standardized GA-map(®) platform and supports\nour strategy to build scalable revenues through partner laboratories,\nreagent-kit sales and new diagnostic applications.”\n\n\n*Includes a positive impact from customer pre-payment.\n\nDefinitions:\nEquity ratio:                        Shareholder’s\nequity as a proportion of total assets.\nEarnings per share:          Profit/Loss for the period divided by an\naverage number of shares.\nConstant currency:          This year’s sales converted to NOK by\nusing last year’s exchange rates.\n\n\nRevenues and Gross margin\n\nSales revenue (excluding grants) reached NOK 3.8 million in Q1 2026, an\nincrease of 60.2% compared to Q1 2025.\n\nKey product sales (GA map(®) Reagent kits) reached NOK 3.5 million in Q1:\n* Up 68.3% in Q1 2026 compared to Q1 2025. The weaker USD against NOK has\nnegatively impacted sales, and thus the underlying reagent kit sales growth\nhas been even stronger. \nGross margin was NOK 2.8 million in Q1 2026, corresponding to a gross margin\nof 73.2%, compared to NOK 2.0 million and 83.6% in Q1 2025. Gross margin% was\nnegatively affected by the US customs duties and a weaker USD.\n\nCost of goods sold totaled NOK 1.0 million in Q1 2026, compared to NOK 0.4\nmillion in Q1 2025, and included customs duties of NOK 0.3 million (0 in\nQ1-25).\n\nEBITDA\n\nEBITDA in Q1 2026 totaled NOK -3.2 million (NOK -3.1 million in Q1 2025).\n \n\nCash Flow and Liquidity\n* Cash and cash equivalents: NOK 20.0 million on 31 March 2026 compared to NOK\n24.0 million on 31 December 2025.\nHighlights during Q1 2026\n* On February 12, Genetic Analysis announced that its important patent\napplication CA2980637) had been allowed for grant in Canada. The patent covers\nthe Company’s unique algorithm for profiling gut microbiota incorporated in\nthe GA-map(®) technology.\n* On February 19, Genetic Analysis announced that its patent application\nUS2017/0369941 had been allowed for grant by the United States Patent and\nTrademark Office (USPTO). The patent strengthens the protection of GA’s\nproprietary diagnostic technology.\n* On March 12, Genetic Analysis announced the launch of GA-map(®) Dysbiosis\nTest AInsight, an AI-assisted interpretation platform designed to translate\nmicrobiome analysis results into structured and clinically relevant insights,\nsupporting broader adoption of microbiome testing in clinical practice.\nHighlights after the end of the period\n* On April 30, Genetic Analysis announced its attendance at Digestive Disease\nWeek (DDW) congress in Chicago, May 3 - 5 2026. The company used the meeting\nto launch AInsight and highlight its upcoming product, GA-map(®) IBD\nPrecision Dx, a next-generation diagnostic solution for personalized\nmanagement in inflammatory bowel disease (IBD).\n* On May 7, Genetic Analysis announced that the USPTO granted a U.S. patent\nno. 12,596,121 covering a diagnostic method to assess the likelihood that IBS\npatients will respond to treatment with a low-FODMAP diet or Faecal Microbiota\nTransplant (FMT).\nFor further information, please contact:\nRonny Hermansen, CEO\nE-mail: rh@genetic-analysis.com\n\nThis disclosure contains information that Genetic Analysis AS is obliged to\nmake public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The\ninformation was submitted for publication, through the agency of the contact\nperson, at the time indicated by Genetic Analysis AS news distributor upon\npublication of this press release.\n\nAbout Genetic Analysis:\nGenetic Analysis AS (GA) is a science-based diagnostic company and pioneer in\nthe human microbiome field with more than 15 years of expertise in research\nand product development. The unique GA-map® platform is based on a\npre-determined multiplex targets approach specialized for simultaneous\nanalysis of a large number of bacteria in one reaction. The test results are\ngenerated by utilizing the clinically validated cutting edge GA-map® software\nalgorithm. This enables immediate results without the need for further\nbioinformatics work. GA’s vision is to become the leading company for\nstandardized gut microbiota testing worldwide, and GA is committed to help\nunlocking and restoring the human microbiome through its state-of-the-art\ntechnology. GA employs a team of highly qualified employees with scientific\nbackgrounds and competence in sales, operations, bioinformatics, molecular\nbiology, and bioengineering.\n\nFor more general information: www.genetic-analysis.com\n\nInterested in reading more about GA's products? Please visit www.ga-map.com\n\nStay updated on GA and sign up for more investor-related information:\nhttps://www.geneticanalysis.com/subscriptions/\n\nhttps://news.cision.com/genetic-analysis-as/r/publication-of-interim-report-january---march-2026%2Cc4354373\n\nGA Q1 2026 - final version\n(https://mb.cision.com/Main/20846/4354373/4119526.pdf)\n\nGA press release - Q1 2026\n(https://mb.cision.com/Public/20846/4354373/94a3c200f8268b75.pdf)\n\n\n\n(c) Copyright Waymaker BIT News - Cision 2026","article_body_html":"","raw_payload":{"data":{"id":"nWkrbdw1Ss","title":"Publication of interim report January - March 2026","author":"Cision","ticker":"GEAN","created":"2026-05-28T06:45:08.456Z","tickers":["GEAN"],"exchange":"","article_body":"Genetic Analysis AS\nOSLO, NORWAY - May 28, 2026: Genetic Analysis AS (\"GA\" or the \"Company\")\nhereby publishes the interim report for the period January - March 2026. The\nreport is available as an attached file to this release and on the Company's\nwebsite. Below is a summary of the report.\n\nRonny Hermansen, CEO of Genetic Analysis, comments:\n“The first quarter of 2026 was marked by continued progress for Genetic\nAnalysis, with strong growth in recurring GA-map(®) kit sales and further\nadvancement of our microbiome-based diagnostics pipeline. The development\nconfirms the relevance of our standardized GA-map(®) platform and supports\nour strategy to build scalable revenues through partner laboratories,\nreagent-kit sales and new diagnostic applications.”\n\n\n*Includes a positive impact from customer pre-payment.\n\nDefinitions:\nEquity ratio:                        Shareholder’s\nequity as a proportion of total assets.\nEarnings per share:          Profit/Loss for the period divided by an\naverage number of shares.\nConstant currency:          This year’s sales converted to NOK by\nusing last year’s exchange rates.\n\n\nRevenues and Gross margin\n\nSales revenue (excluding grants) reached NOK 3.8 million in Q1 2026, an\nincrease of 60.2% compared to Q1 2025.\n\nKey product sales (GA map(®) Reagent kits) reached NOK 3.5 million in Q1:\n* Up 68.3% in Q1 2026 compared to Q1 2025. The weaker USD against NOK has\nnegatively impacted sales, and thus the underlying reagent kit sales growth\nhas been even stronger. \nGross margin was NOK 2.8 million in Q1 2026, corresponding to a gross margin\nof 73.2%, compared to NOK 2.0 million and 83.6% in Q1 2025. Gross margin% was\nnegatively affected by the US customs duties and a weaker USD.\n\nCost of goods sold totaled NOK 1.0 million in Q1 2026, compared to NOK 0.4\nmillion in Q1 2025, and included customs duties of NOK 0.3 million (0 in\nQ1-25).\n\nEBITDA\n\nEBITDA in Q1 2026 totaled NOK -3.2 million (NOK -3.1 million in Q1 2025).\n \n\nCash Flow and Liquidity\n* Cash and cash equivalents: NOK 20.0 million on 31 March 2026 compared to NOK\n24.0 million on 31 December 2025.\nHighlights during Q1 2026\n* On February 12, Genetic Analysis announced that its important patent\napplication CA2980637) had been allowed for grant in Canada. The patent covers\nthe Company’s unique algorithm for profiling gut microbiota incorporated in\nthe GA-map(®) technology.\n* On February 19, Genetic Analysis announced that its patent application\nUS2017/0369941 had been allowed for grant by the United States Patent and\nTrademark Office (USPTO). The patent strengthens the protection of GA’s\nproprietary diagnostic technology.\n* On March 12, Genetic Analysis announced the launch of GA-map(®) Dysbiosis\nTest AInsight, an AI-assisted interpretation platform designed to translate\nmicrobiome analysis results into structured and clinically relevant insights,\nsupporting broader adoption of microbiome testing in clinical practice.\nHighlights after the end of the period\n* On April 30, Genetic Analysis announced its attendance at Digestive Disease\nWeek (DDW) congress in Chicago, May 3 - 5 2026. The company used the meeting\nto launch AInsight and highlight its upcoming product, GA-map(®) IBD\nPrecision Dx, a next-generation diagnostic solution for personalized\nmanagement in inflammatory bowel disease (IBD).\n* On May 7, Genetic Analysis announced that the USPTO granted a U.S. patent\nno. 12,596,121 covering a diagnostic method to assess the likelihood that IBS\npatients will respond to treatment with a low-FODMAP diet or Faecal Microbiota\nTransplant (FMT).\nFor further information, please contact:\nRonny Hermansen, CEO\nE-mail: rh@genetic-analysis.com\n\nThis disclosure contains information that Genetic Analysis AS is obliged to\nmake public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The\ninformation was submitted for publication, through the agency of the contact\nperson, at the time indicated by Genetic Analysis AS news distributor upon\npublication of this press release.\n\nAbout Genetic Analysis:\nGenetic Analysis AS (GA) is a science-based diagnostic company and pioneer in\nthe human microbiome field with more than 15 years of expertise in research\nand product development. The unique GA-map® platform is based on a\npre-determined multiplex targets approach specialized for simultaneous\nanalysis of a large number of bacteria in one reaction. The test results are\ngenerated by utilizing the clinically validated cutting edge GA-map® software\nalgorithm. This enables immediate results without the need for further\nbioinformatics work. GA’s vision is to become the leading company for\nstandardized gut microbiota testing worldwide, and GA is committed to help\nunlocking and restoring the human microbiome through its state-of-the-art\ntechnology. GA employs a team of highly qualified employees with scientific\nbackgrounds and competence in sales, operations, bioinformatics, molecular\nbiology, and bioengineering.\n\nFor more general information: www.genetic-analysis.com\n\nInterested in reading more about GA's products? Please visit www.ga-map.com\n\nStay updated on GA and sign up for more investor-related information:\nhttps://www.geneticanalysis.com/subscriptions/\n\nhttps://news.cision.com/genetic-analysis-as/r/publication-of-interim-report-january---march-2026%2Cc4354373\n\nGA Q1 2026 - final version\n(https://mb.cision.com/Main/20846/4354373/4119526.pdf)\n\nGA press release - Q1 2026\n(https://mb.cision.com/Public/20846/4354373/94a3c200f8268b75.pdf)\n\n\n\n(c) Copyright Waymaker BIT News - Cision 2026"},"type":"article","timestamp":"2026-05-28T06:45:08.549573573Z","server_sent_at_ms":1779950708549},"received_at":"2026-05-28T06:45:08.603Z","source_url":"https://news.cision.com/genetic-analysis-as/r/publication-of-interim-report-january---march-2026%2Cc4354373"},"analysis":{"id":"36821","press_release_id":"47388","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Gross margin compression due to US customs duties","Continued operating losses (negative EBITDA)","Small absolute revenue scale (NOK 3.8M)"],"eventType":"earnings","narrative":"Genetic Analysis reported Q1 2026 revenue of NOK 3.8 million, a 60.2% increase year-over-year, driven by a 68.3% surge in sales of its GA-map reagent kits.\n\nGross margin stood at 73.2% (NOK 2.8 million), down from 83.6% in the prior year, due to US customs duties and a weaker USD. EBITDA was a loss of NOK 3.2 million, broadly in line with the previous year.\n\nThe company highlighted significant IP progress, including the granting of key patents in Canada and the US for its microbiome profiling algorithms, and launched the AI-assisted AInsight platform for dysbiosis testing.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Strong top-line growth and key patent wins for niche microbiome diagnostic player, though margin pressure from tariffs persists."},"keyFigures":{"revenue":"3.8 million NOK","revenueYoy":"60.2%","customDimensions":{"ebitda":"-3.2 million NOK","customs_duties":"0.3 million NOK","gross_margin_nok":"2.8 million NOK","gross_margin_pct":"73.2%","key_product_sales":"3.5 million NOK","cost_of_goods_sold":"1.0 million NOK","cash_and_equivalents":"20.0 million NOK","key_product_sales_yoy":"68.3%"}},"quotedText":"The first quarter of 2026 was marked by continued progress for Genetic Analysis, with strong growth in recurring GA-map(®) kit sales and further advancement of our microbiome-based diagnostics pipeline.","namedEntities":{"people":[{"name":"Ronny Hermansen","role":"CEO"}],"products":["GA-map(®)","GA-map(®) Dysbiosis Test AInsight","GA-map(®) IBD Precision Dx"],"companies":[{"name":"Genetic Analysis AS","ticker":"GEAN"},{"name":"United States Patent and Trademark Office","relationship":"regulatory body"}],"dollarAmounts":[{"amount":"NOK 3.8 million","context":"Q1 2026 sales revenue"},{"amount":"NOK 3.5 million","context":"Q1 2026 key product sales (GA map Reagent kits)"},{"amount":"NOK 2.8 million","context":"Q1 2026 gross margin"},{"amount":"NOK 2.0 million","context":"Q1 2025 gross margin"},{"amount":"NOK 1.0 million","context":"Q1 2026 cost of goods sold"},{"amount":"NOK 0.4 million","context":"Q1 2025 cost of goods sold"},{"amount":"NOK 0.3 million","context":"customs duties included in COGS"},{"amount":"NOK -3.2 million","context":"Q1 2026 EBITDA"},{"amount":"NOK -3.1 million","context":"Q1 2025 EBITDA"},{"amount":"NOK 20.0 million","context":"Cash and cash equivalents as of March 31, 2026"},{"amount":"NOK 24.0 million","context":"Cash and cash equivalents as of December 31, 2025"}]},"materialImpact":{"score":2,"reasoning":"Small-cap biotech reporting Q1 results with strong top-line growth (60% YoY) and key IP milestones (patents granted), but remains deeply unprofitable (EBITDA -NOK 3.2M) with low absolute revenue scale (NOK 3.8M). The news is positive for momentum but not market-moving due to the small size of the company and the routine nature of quarterly reporting."},"tickerRelevance":{"others":[],"primary":"GEAN"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":["product_launch","regulatory"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"quarterly_earnings","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"event_type":"earnings","event_type_secondary":["product_launch","regulatory"],"sentiment":"bullish","material_impact_score":2,"narrative":"Genetic Analysis reported Q1 2026 revenue of NOK 3.8 million, a 60.2% increase year-over-year, driven by a 68.3% surge in sales of its GA-map reagent kits.\n\nGross margin stood at 73.2% (NOK 2.8 million), down from 83.6% in the prior year, due to US customs duties and a weaker USD. EBITDA was a loss of NOK 3.2 million, broadly in line with the previous year.\n\nThe company highlighted significant IP progress, including the granting of key patents in Canada and the US for its microbiome profiling algorithms, and launched the AI-assisted AInsight platform for dysbiosis testing.","key_figures":{"revenue":"3.8 million NOK","revenueYoy":"60.2%","customDimensions":{"ebitda":"-3.2 million NOK","customs_duties":"0.3 million NOK","gross_margin_nok":"2.8 million NOK","gross_margin_pct":"73.2%","key_product_sales":"3.5 million NOK","cost_of_goods_sold":"1.0 million NOK","cash_and_equivalents":"20.0 million NOK","key_product_sales_yoy":"68.3%"}},"named_entities":{"people":[{"name":"Ronny Hermansen","role":"CEO"}],"products":["GA-map(®)","GA-map(®) Dysbiosis Test AInsight","GA-map(®) IBD Precision Dx"],"companies":[{"name":"Genetic Analysis AS","ticker":"GEAN"},{"name":"United States Patent and Trademark Office","relationship":"regulatory body"}],"dollarAmounts":[{"amount":"NOK 3.8 million","context":"Q1 2026 sales revenue"},{"amount":"NOK 3.5 million","context":"Q1 2026 key product sales (GA map Reagent kits)"},{"amount":"NOK 2.8 million","context":"Q1 2026 gross margin"},{"amount":"NOK 2.0 million","context":"Q1 2025 gross margin"},{"amount":"NOK 1.0 million","context":"Q1 2026 cost of goods sold"},{"amount":"NOK 0.4 million","context":"Q1 2025 cost of goods sold"},{"amount":"NOK 0.3 million","context":"customs duties included in COGS"},{"amount":"NOK -3.2 million","context":"Q1 2026 EBITDA"},{"amount":"NOK -3.1 million","context":"Q1 2025 EBITDA"},{"amount":"NOK 20.0 million","context":"Cash and cash equivalents as of March 31, 2026"},{"amount":"NOK 24.0 million","context":"Cash and cash equivalents as of December 31, 2025"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-28T06:45:29.403Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"quarterly_earnings","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"durationMs":20772,"modelName":"george-droid-qwen-72b"}}